Arrowhead Research
ARWR

$22.22

4.43%

Market Cap: $2.76B

About: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Employees: 525

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

87% more call options, than puts

Call options by funds: $35.5M | Put options by funds: $19M

67% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 5 (+2) [Q2]

10% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 86

1.14% more ownership

Funds ownership: 77.57% [Q1] → 78.71% (+1.14%) [Q2]

0% more funds holding

Funds holding: 268 [Q1] → 268 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 34

8% less capital invested

Capital invested by funds: $2.75B [Q1] → $2.54B (-$207M) [Q2]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$55

148%

upside

Avg. target

$63

184%

upside

High target

$90

305%

upside

8 analyst ratings

8 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	170%upside $60	Buy Reiterated	5 Sept 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	170%upside $60	Buy Reiterated	3 Sept 2024
B. Riley Securities Mayank Mamtani 50% 1-year accuracy 13 / 26 met price target	148%upside $55	Buy Reiterated	12 Aug 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	170%upside $60	Buy Reiterated	23 Jul 2024
Chardan Capital Keay Nakae 35% 1-year accuracy 19 / 55 met price target	170%upside $60	Buy Maintained	17 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ARWR published over the past 30 days

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Shares of Arrowhead Pharmaceuticals (ARWR) gained Tuesday after the biotech firm announced positive results in a late-stage study of its experimental treatment for a rare metabolic disorder, and said it plans to request regulatory approval to market it.

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no approved treatments in the U.S. PALISADE successfully met its primary endpoint and all multiplicity-controlled key secondary endpoints, including statistically significant reductions in triglycerides (TGs), apolipopr.

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of Cardiology (ESC) Congress 2024, being held in London August 30 through September 2, 2024. The company will also host a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT. Details about the ESC presentation are listed below. European Society of Cardiology C.

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference August 14, 2024 2:00 PM ET Company Participants Vincent Anzalone - Vice President and Head of Investor Relations Dr. Carel Le Roux - Chair of Metabolic Medicine, University College Dublin Erik Bush - Senior Vice President, Biology Tao Pei - Senior Vice President, Discovery Chemistry James Hamilton - SVP, Discovery and Translational Medicine Operator Good afternoon, and welcome to the Arrowhead Summer Series of R&D Webinars Part 4. As a reminder, all participants are in a listen-only mode.

Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript)

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic diseases. In preclinical studies to date, these candidates demonstrated the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle m.

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting a conference call today, August 8, 2024, at 4:30 p.m. ET to discuss the results. “Arrowhead had a very productive quarter with several high-profile presentations at medical and scientific congresses, as well as publications in high impact journals. Our clinical results have been strong and are receiving.

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has entered into a strategic financing agreement with Sixth Street for significant, long-term, non-dilutive capital to fund innovation and growth opportunities across Arrowhead's robust and diverse pipeline of RNAi therapeutics. The $500 million senior secured credit facility includes $400 million funded at close with an additional $100 million available at Arrowhead's option, subject to mu.

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 25, 2024, the Company's Board of Directors approved “inducement” grants to 33 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 60,900 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceutical: Driving To Commercialization

Arrowhead Pharmaceuticals has a promising pipeline of drug candidates based on RNAi methodology. It has developed a tighter focus to push its most promising cardiometabolic drug (Plozasiran) toward FDA approval and commercialization. The new focus is manifested in practical ways that enhance the prospects of commercialization.

Arrowhead Pharmaceutical: Driving To Commercialization

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclus.

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

See News Rankings